Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI) in a research report issued on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. Morgan Stanley raised their price target on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 11th. JPMorgan Chase & Co. increased their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Cantor Fitzgerald raised Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Nine research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies has an average rating of “Moderate Buy” and a consensus target price of $103.62.

Intra-Cellular Therapies Trading Down 0.1 %

Shares of NASDAQ ITCI opened at $127.01 on Friday. Intra-Cellular Therapies has a 1-year low of $62.78 and a 1-year high of $128.00. The company has a 50-day moving average of $101.55 and a two-hundred day moving average of $86.33. The company has a market cap of $13.50 billion, a PE ratio of -145.99 and a beta of 0.72.

Insider Buying and Selling

In other Intra-Cellular Therapies news, President Michael Halstead sold 22,869 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total transaction of $2,038,085.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at $91,834,228.20. This trade represents a 4.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Intra-Cellular Therapies

Several hedge funds have recently modified their holdings of the stock. True Wealth Design LLC bought a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at about $32,000. GAMMA Investing LLC lifted its stake in Intra-Cellular Therapies by 46.3% in the 4th quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares during the last quarter. Capital Performance Advisors LLP bought a new position in Intra-Cellular Therapies during the third quarter worth about $74,000. Venturi Wealth Management LLC acquired a new position in Intra-Cellular Therapies during the fourth quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in Intra-Cellular Therapies during the third quarter worth approximately $97,000. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.